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Abstract 
A Cu(II) complex was obtained from the reaction of 4-(diethylamino)-3-quinolin-3-ylimino-
methyl-2-phenol with [CuCl2(PPh3)2]. The ligand coordinated to the metal ion in a monobasic 
bidentate fashion. The molecular structure of the complex has been confirmed by single crystal 
X-ray diffraction. Both the ligand and complex were characterized by various spectroscopic 
techniques. Using the UV-visible and fluorescence spectroscopic studies, the binding interactions 
of the compounds with CT-DNA and bovine serum albumin protein were evaluated. The results 
indicated that the compounds are efficient DNA/protein binders. The cytotoxicity of the ligand 
and complex against A549 (lung cancer) and MCF7 (breast cancer) cell lines was also 
investigated in vitro conditions using the MTT assay method which showed significant 
anticancer activity.  
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Introduction  
Most of the drugs that are used at present for cancer treatment are cytotoxic (cell-killing), 
affecting in one way or the other with the functioning of the DNA in cells. However, the biggest 
challenge in the development of new anticancer drugs is to find chemotherapeutic agents not 
only with high efficacy but also with low toxicity. It has been observed that though cisplatin has 
been used most successfully in the treatment of various types of cancers, it has been associated 
with side effects in addition to inherited or acquired resistance [1,2]. Hence, chemists all over the 
world have been forced to look for an alternative approach in finding human friendly metal 
complexes to enhance the pharmacological properties. From among the various metal complexes 
studied so far, copper ion based complexes have been proved to be a promising alternative to 
platinum drugs [3]. Copper-based antineoplastic agents have shown remarkable results not only 
to test the altered metabolism of cancer cells but also to differentiate between cancer and normal 
  
cells [4]. In this connection, several copper-based synthetic nucleases have been reported [5-7] 
and a few of them have been found to cleave DNA hydrolytically [8,9]. During the last several 
years, there has been a consistent and continuous effort in finding out the mode and extent of 
binding of metal complexes to DNA and protein and also to obtain vital information on 
understanding the cleavage properties of metal complexes for their biological applications.  
Numerous inorganic chemists have chosen copper for its bio-essential activity and oxidative 
nature to establish its complexes for medical applications [10–13]. In this area, copper 
complexes containing heterocyclic bases as ligands have been extensively explored in view of 
their strong interactions with DNA and of their cytotoxic activity [14–16]. In addition to this, 
copper complexes with their biologically accessible redox potentials have shown high 
nucleobase affinity with DNA [17-21] besides exhibiting an essential alternative to platinum 
drugs [22-28]. From the point of ligand used to prepare useful metal complexes, the combination 
of nitrogen containing heterocyclic ring and azomethine moiety might prove to be useful due to 
their potential biological and catalytic activities. Further, quinolines as well as their derivatives 
are also a class of ligands exhibiting a wide range of biological applications. In fact, some 
quinoline based Schiff base ligands and their Cu(II) complexes have been reported to show 
interesting pharmacological properties [29-34]. Our perusal on the literature has indicated that no 
attention has been paid to explore the biological properties of 4-(diethylamino)-3-quinolin-3-
ylimino-methyl-2-phenol and its Cu(II) complexes. Hence, we carried out the reaction of 4-
(diethylamino)-3-quinolin-3-ylimino-methyl-2-phenol with [CuCl2(PPh3)2] and report the 
biological studies done on the ligand and that of the new complex. 
Results and discussion 
Synthesis  
The synthetic route to the ligand and its Cu(II) complex are shown in Scheme 1 and they have 
been characterized by various spectroscopic techniques as discussed below. The ligand and 
complex are air stable and soluble in chloroform, dichloromethane, methanol, ethanol, 
dimethylformamide and dimethylsulfoxide. 
  
 
Scheme 1. Synthetic route of the ligand and its Cu(II) complex. 
Spectroscopy 
In the electronic spectra of ligand, three bands were observed in the region 282-402 nm, which 
are assigned to intra ligand transitions. Spectra of the complex exhibited two bands, the band   
observed at 254 nm was assigned to intra ligand transition and the band at 383 nm corresponds to 
ligand to metal charge transfer transition [35-37]. The IR spectrum, a band observed at 1628 cm-1 
due to the C=N stretching of the ligand has been found shifted to 1606 cm-1 in the spectra of the 
complex, indicating coordination of the azomethine nitrogen atom to the Cu(II) ion. The band at 
3432 cm-1 due to the –OH group in the free ligand disappeared completely in the spectra of the 
complex due to coordination of phenolic oxygen after deprotonation [38,39]. The 1H-NMR 
spectra of the ligand (Figure S1), showed a sharp singlet at δ 8.93 ppm corresponding to the 
presence of a hydroxy group in the free ligand. A doublet at δ 8.42-8.43 ppm corresponds to the 
presence of the CH=N azomethine proton [40]. While a quartet observed around at δ 2.49-2.53 
ppm corresponds to the CH2N group of protons in the ligand, a triplet observed at δ 1.11-1.14 
ppm has been assigned to the terminal methylene group of protons [39]. The aromatic protons 
resonances of the ligand were observed in the range at δ 6.11-7.99 ppm. 13C NMR spectra of the 
ligand showed the chemical shift values of each carbon in the expected region (Figure S2). The 
signal observed at δ 152.40 ppm has been assigned to the azomethine (CH=N) carbon [41], with 
the aromatic carbons resonances in the region of 168.32-109.40 ppm [42]. The ˗CH2 carbon 
  
signal appeared at δ 49.21 ppm and the ˗CH3 carbon was observed at 17.78 ppm in the ligand 
respectively [43,44]. The +2 oxidation state of the copper ion in the complex was confirmed by 
X-band EPR measured at room temperature. The copper complex showed well resolved isotropic 
resonance typical of square planar Cu(II) system (Figure S3). From the g value of 2.01, it is 
proposed that the unpaired electron of Cu(II) ion is present in the dx2−y2orbital [45]. 
X-ray crystallography 
The complex crystallized in the triclinic space group P-1 with half a molecule in the asymmetric 
unit (Z’=0.5).  Two ligands coordinated to the copper ion in a monobasic bidentate fashion 
through the imine nitrogen (N1) and phenolic oxygen (O1) forming a six-member chelate rings.  
The Cu(II) ion showed approximately square planar geometry with the two unique O-Cu-N 
angles of 92.03(4)° and 87.97(4)°, the rms deviation of the Cu from the ONON plane was 
necessarily 0 as a result of the Cu being sat on an inversion center. Surprisingly, the bidentate 
chelating ligand replaced all the triphenylphospine ligands and chloride ions from the Cu(II) 
precursor (Figure 1). Crystal data and refinement details for the complex are presented in (Table 
1). Important bond Length (Å) and bond angle (°) of the complex given in Table S1 (supporting 
information). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Crystal structure of the complex with atomic numbering scheme shown. Hydrogen 
atoms are omitted for clarity and anisotropic displacement parameters are depicted at the 50 % 
probability level. Symmetry code i = -x, 1-y, -z. 
  
Table 1.Crystal data and structure refinement for complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA binding studies 
In order for any compound to be tested for treating multiple pathologies including cancer, it is 
necessary to investigate the binding of such compound with DNA [46,47]. One of the easiest 
ways is to observe the changes in the electronic absorption spectra of the compounds as a 
function of added DNA. Hence, we carried out the interaction of our compounds (10 µM) with 
Idendification code Complex  
Empirical formula  C40H40CuN6O2 
Formula weight  700.32 
Temperature/K  100(2)  
Crystal system  Triclinic  
Space group  P-1 
a/Å  8.8927(4) 
b/Å 9.2553(4) 
c/Å  12.1514(5) 
α/° 106.708(2) 
β/°  100.885(4)  
γ/° 114.778(2) 
Volume/Å3 846.67(7) 
Z  1  
ρcalcg/cm3 1.374  
μ/mm-1 0.691  
F(000)  367.0  
Crystal size/mm3 0.43 × 0.32 × 0.20 
Radiation  MoKα (λ = 0.71073)  
2θ range for data collection/°  3.594 to 55.882 
Index ranges  
-11 ≤ h ≤ 11  
-12 ≤ k ≤ 12,  
-15 ≤ l ≤ 15 
Reflections collected  15639 
Rint / Rsigma 0.0199 / 0.0179 
Data/restraints/parameters  4054/0/225 
Goodness-of-fit on F2 1.063 
Final R indexes [I>=2σ (I)]  R1 = 0.0259, wR2 = 0.0674 
Final R indexes [all data]  R1 = 0.0272, wR2 = 0.0682 
Largest diff. peak/hole / e Å-3 0.39/-0.31 
  
DNA (0-100 µM) and the spectral changes observed are shown in (Figure 2). It can be seen from 
the figure that as and when the concentration of DNA is increased, a hyperchromism with a blue 
shift of 4 nm was observed for the ligand. But, for the complex, a hypochromism with a red shift 
of 3 nm was observed which indicates the existence of an intercalative mode of binding [48]. 
Generally, compounds binding to DNA through intercalation results in hyperchromism or 
hypochromism with or without a small red or blue shift, due to a strong stacking interaction 
between the planar aromatic chromophore of the compound and the base pairs of DNA [49,50]. 
Further, to get an idea on the binding strength of the compounds, the intrinsic binding constants 
(Kb) of them with CT-DNA have to be determined from the following equation. 
 [DNA]/[εa-εf] = [DNA]/[εb-εf] + 1/Kb[εb-εf] 
where, [DNA] is the concentration of DNA in base pairs, εa is the extinction coefficient of the 
complex at a given DNA concentration, εf is the extinction coefficient of the complex in free 
solution and εb is the extinction coefficient of the complex when fully bound to DNA. Figure 3 
shows the plot of [DNA]/( εa-εf) versus [DNA]  which gave a slope and an intercept equal to 1/[ 
εa-εf] and 1/Kb[εb-εf]. The intrinsic binding constant Kb is the ratio of the slope to the intercept 
and binding constants of  0.5873 × 105 and 1.34942 × 105 M-1 have been obtained for the ligand and 
the complex indicating that the complex exhibited a better binding than that of the free ligand. The 
higher binding affinity of the Cu(II) complex may be due to the extension of the π system of the 
intercalated ligand through coordination to the metal ion and due to a greater planar area of the 
complex than that of the free ligand thereby penetrating more deeply into and stacks more 
strongly with the base pairs of DNA. 
 
  
 
Figure 2. Electronic titration spectra of ligand  (A), complex  (B). Arrow shows that the absorption  
     intensities increase and decrease upon increasing DNA concentration. 
 
 
Figure 3. Plots of [DNA]/(εa-εf) versus [DNA]. 
Protein binding studies 
In addition to DNA binding, it is further essential to know the nature of the binding of 
compounds to proteins to obtain information on the relationship between structure and functions 
of proteins. Such information can be obtained from the changes observed in the fluorescence 
  
spectrum of BSA (Bovine Serum Albumin) on the incremental addition of new compounds to 
BSA. Hence, we titrated BSA with different concentrations of the compounds (0-50 μM) and the 
results are shown in (Figure 4). It can be noticed that there is a significant decrease in the 
fluorescence intensity of BSA on the subsequent addition of the compounds (A = ligand, B = 
complex). The decrease in fluorescence intensity with the blue shift does indicate the interaction 
among the ligand and complex with BSA. Using the Stern–Volmer relationship I0/I = 1 + Kq [Q] 
(where I0 and I demonstrate the fluorescence intensities in the absence and presence of a 
quencher, respectively, Kq is a linear Stern–Volmer quenching constant, and [Q] is the quencher 
concentration), one can calculate the quenching constant (Kq) from the plot of I
0/I versus [Q] 
(Figure 5). Further, the number of binding sites (n) and the binding constant (Kb) values can also 
be obtained from Scatchard equation log[(F0− F)/F] = log Kb + n log[Q] (where Kb is the binding 
constant of the compounds with BSA and n is the number of binding sites ) when small 
molecules bind independently to a set of equivalent sites on a macromolecule. From the plot of 
log[(F0− F)/F] versus log[Q] (Figure 6), the number of binding sites (n) and the binding constant 
(Kb) values have been obtained. The calculated value of n is around 0.69 and 1.1 for the ligand 
and complex, showing the existence of a single binding site in BSA for the compounds. The 
values of Kq and Kb are shown in Table 2 which indicate  that the complex interacts with BSA 
more strongly than the  free ligand, a result which is similar to the one obtained from the CT-
DNA absorbance titration [51]. 
 
Table 2. Quenching constant (Kq), binding constant (Kb), and number of binding sites (n) values. 
 
 
 
 
 
Compound     Kq (M
-1)           Kb(M
-1)         n 
Ligand          1.17 × 102            6.41 × 103      0.69 
Complex       2.06  × 104        8.13 × 103      1.1 
  
 
Figure 4. Fluorescence quenching titration of BSA with the compounds. 
 
Figure 5. Stern–Volmer plot of the compounds with BSA. 
 
  
 
Figure 6. Scatchard plot of the compounds with BSA. 
 
In these types of studies, it is also important to determine the mechanism of quenching since 
there are two type of quenching namely, dynamic and static. Fluorophore-quencher complex 
formation in the ground state refers to static quenching while such a formation in the excited 
state corresponds to dynamic quenching. UV-Vis absorption spectroscopy can be employed 
determine the type of quenching and hence, we measured the UV-Vis spectra of BSA in the 
absence and presence of the test compounds and the spectra recorded are shown in (Figure 7). 
The addition of the Cu complex to a fixed concentration of BSA led to a gradual increase in the 
intensity of BSA absorption at the same wavelength due to the interaction between the complex 
and protein, which is ascribed to the static quenching [52]. 
  
 
Figure 7. Absorption titration of BSA with the compounds. 
 
Synchronous fluorescence spectra 
Tyrosine, tryptophan and phenylalanine residues are responsible for the fluorescence properties 
of BSA and one can find out the presence of any of these residues by measuring the synchronous 
fluorescence spectra of BSA with the compounds under study [53]. Hence, we measured the 
synchronous fluorescence spectra of BSA in the presence and absence of increasing 
concentrations (0-50 μM) of compounds at different Δλ. It is well known that atΔλ = 15 nm is 
characteristic of tyrosine residue, while the corresponding spectrum at Δλ = 60 nm is 
characteristic of tryptophan. The synchronous fluorescence spectra of BSA with various 
concentrations of test compounds were recorded. On the adding of the compounds to BSA, the 
fluorescence intensity at 342 nm decreased both for the ligand and the complex (Figure 8).The 
synchronous fluorescence spectra results clearly showed that the fluorescence intensity of both 
tryptophan and tyrosine micro-regions was affected with increasing concentration of the 
compounds [54-56]. 
  
 
Figure 8. Synchronous fluorescencetitration of BSA with the compounds at Δλ = 60 nm (A=    
      ligand, B = complex). 
Cytotoxicity 
The positive results obtained from the DNA and protein binding studies prompted us further to 
explore their in vitro cytotoxicity on cancer cell lines and we carried out the studies against A549 
(lung cancer) and MCF7 (breast cancer) cell lines. The cell death inducing ability of the 
compounds was monitored by using the AO/EB staining assay and DAPI fluorescence study. 
The inhibition at 24 h of cancer cell growth at 50 % level and IC50 values of the ligand and the 
complex are shown in (Table 3) and (Figure 9). It is important to mention that the copper(II) 
complex presented herein showed better growth inhibitory effect than the  previously reported 
copper complexes [57-60]. The cytotoxic properties of this new Cu(II) complex can be  
attributed to the extended planar structure induced by the chelation of the quinoline ligand to the 
copper ion in the complex. The ligand also exhibited a moderate cytotoxic effect on A549 and 
MCF7 cancer cell lines compared to doxorubicin and cisplatin, with the copper(II) complex 
showed better activity against MCF7 cell line.  
 
 
 
 
 
 
  
              Table 3. The IC50 values of the Compounds. 
 
 
 
 
 
Acridine orange /Ethidium bromide (AO/EtBr) staining Method 
To establish the potential of any compound for a therapeutic use, it is essential to look at the 
apoptotic activity of the compound through apoptotic staining fluorescence microscopic 
analysis.Hence, the fluorescence microscopic images of A549-A and MCF7-B cancer cells in the 
absence (control) and in the presence of the free ligand and the new Cu complex have been 
recorded and the results are shown in (Figure 9). From the figure, it is clear that the untreated 
A549 and MCF7 cancer cells (control (a), (b)) did not show any significant adverse effect 
compared to that treated with the compounds (treated (c), (d)). Besides, it can also be seen that 
on the addition of the test compounds to the cancer cells, the green colour of cells are converted 
into orange/red colour cells which is due to induced apoptosis and the nuclear condensation 
effect on the cells. The results do indicate that the compounds have the ability to significantly 
induce the apoptosis in selected cancer cells.  
 
                      IC50 values (μM) 
Compound        A549            MCF7 
Ligand               34± 1.8          27± 1.7 
Complex          30± 1.5          24± 1.5 
Doxorubicin    15± 1.2          16± 1.3 
Cisplatin          25 ± 2.1         18.7 ± 0.1 
  
 
                                          (A)                                                                 (B) 
Figure 9. AO/EB stained A549 (A) and MCF7 (B) (a, b control and c, d, are treated with the 
ligand and complex) cells after 24 h incubation. The yellow or red color cells indicate early 
apoptotic cells. 
DAPI staining method 
Since it is necessary to confirm the nuclear condensation and fragmentation of the test 
compounds, fluorescence microscopy images of lung and breast cancer cells were taken after 
staining with DAPI for 24 h in the absence and presence of compounds and the results are shown 
in (Figure 10). It can be seen from the  figure that the untreated cells (a, b) didn’t show any 
significant changes whereas the ones treated with the compounds (c, d) showed bright patches, 
which suggest the presence of condensed chromatins and nuclear fragmentations in the cancer 
cells. Thus, from the results of MTT assay and fluorescence microscopy analysis, we feel that the 
new complex has the potential to be tried as a potent therapeutic agent. 
 
  
 
                                          (A)                                                              (B) 
Figure 10. DAPI images A549 (A) and MCF7 (B) (a, b control and c, d, are treated with the 
ligandand complex). The blue patches show nuclear fragmentations in the cancer cells. 
Conclusion 
A new Cu(II) complex synthesized has been fully characterized by using analytical and  various 
spectral studies including the structure by  X-ray crystallographic techniques. The ligand 
coordinated to the metal ion in a monobasic bidentate fashion. Binding study of both the ligand 
and complex with CT-DNA has been carried out which showed that they interact through 
intercalation mode. From the UV-visible and fluorescence spectroscopic studies, the binding 
interactions of the compounds with CT-DNA and bovine serum albumin protein were evaluated. 
Furthermore, the compounds were tested against A549 (lung cancer) and MCF7 (breast cancer) 
cell lines and the results indicated significant cytotoxicity as evidenced by the IC50 values 
compared to the doxorubicin and cisplatin. The morphological changes examined by staining 
method suggested that the cell death mechanism was through apoptosis. The higher binding 
affinity and cytotoxic activity of the Cu(II) complex may be due to the extension of the π system 
of the intercalated ligand.  
EXPERIMENTAL SECTION 
Materials and methods 
All the chemicals were purchased from sigma-Aldrich and were used as received. In the case of 
solvents, standard procedures were followed to purify them [61]. The metal complex, 
[CuCl2(PPh3)2] and ligand were prepared following the procedures reported in the literature 
  
[62,63]. Infrared spectra of the ligand and the metal complex were recorded as KBr discs using a 
Jasco FT-IR spectrophotometer. The melting points were recorded with a Lab India melting 
point apparatus. Elemental analyses were performed on a Vario EL III Elementaranalyser 
instrument. The electronic spectra of the compounds were recorded using a Jasco V-630 
spectrophotometer. Emission spectra were measured using a Jasco FP 6600 spectrofluorometer. 
1H and 13C NMR spectra were recorded on a Bruker AMX 500 NMR spectrometer. The X-band 
EPR spectrum of the complex was recorded at room temperature. DNA binding, protein binding 
[33,34] and cytotoxicity [64] experiments were performed using the reported procedures. 
Synthesis of ligand  
4-(diethylamino)-3-quinolin-3-ylimino-methyl-2-phenol was prepared as per the literature 
method [63] using 3-amino quinoline (1.4 g 0.01 mol) and 4-(Diethylamino)salicylaldehyde (1.9 
g 0.01 mol). On cooling the of the reaction solution, a dark brown precipitate was formed which 
was filtered off. It was then washed with ethanol and dried under vacuum. Yield: 76 %. M.p.: 
186 ºC. Elemental analysis calculated for C20H21N3O (%): C, 75.21; H, 6.63; N, 13.16. Found 
(%): C, 75.18; H, 6.57; N, 13.11. FT-IR (cm-1) with KBr disk: 3432 (ʋOH), 1628 (ʋCH=N). UV-Vis 
(DMSO), λmax(nm) [εmax (dm3 mol˗1 cm˗1)]: 282, 331, 402 (Intra-ligand transition). 1H NMR 
(DMSO-d6, δ ppm, J Hz): 8.93 (s, 1H, ˗OH), 8.42 (d, 1H, C =N, J=4), 7.1-7.99 (m, 6H, (Ar-H)), 
6.35-6.37 (d, 1H, J=8, (Ar-H)), 6.11-6.12 (d, 1H, J=4, (Ar-H)), 6.10 (s, 1H, (Ar-H)), 2.49-2.53 
(q, 4H, ˗CH2N), 1.11-1.14 (t, 6H, ˗CH3). 13C (DMSO-d6, δ ppm): 168.32 (C17), 152.40 (C11), 
152.18 (C10), 150.92 (C3), 147.34 (C2), 139.71 (C15), 133.49 (C13), 133.18 (C9), 132.32 (C8), 
131.63 (C6), 130.74 (C7), 129.06 (C5), 128.57 (C4), 116.60 (C14), 114.01 (C16), 109.40 (C12), 
49.21 (˗CH2, C), 17.18 (˗CH3, C).   
Synthesis of the Cu(II)complex  
A methanolic solution (10 Cm3) of 4-(diethylamino)-3-quinolin-3-ylimino-methyl-2-phenol 
(0.048 g 0.1517 mmol) was slowly added to [CuCl2(PPh3)2] (0.100 g 0.1517 mmol) dissolved in 
chloroform (20 Cm3) and the mixture was heated under reflux for 5 hours. Upon cooling, the 
resulting solution afforded a reddish brown colored precipitate. It was filtered, washed with 
petroleum ether (60-80 ºC) and dried in vacuum and recrystallized from methanol/DMF. The 
reddish brown crystals obtained were suitable for X-ray diffraction. Yield: 47 %. M.p.:198 ºC. 
Elemental analysis calculated for C40H40N6O2Cu (%): C, 68.60; H, 5.76; N, 12.00. Found (%): C, 
68.54; H, 5.69; N, 11.94. FT-IR (cm-1) with KBr disk: 1606 (ʋCH=N). UV-visible (DMSO), 
  
λmax(nm) [εmax (dm3 mol˗1 cm˗1)]: 254 (Intra-ligand charge transfer); 383 (Ligand to metal charge 
Transfer). EPR (X-band) at room temperature showed a spectrum with a ‘g’ value of 2.01. 
Crystallography 
X-ray diffraction experiments oof the complex was carried out at 100(2) K on a Bruker APEX II 
diffractometer using Mo-Kα radiation (λ = 0.71073 Å). Data collections were performed using a 
CCD area detector. Intensities were integrated in SAINT [65] and absorption corrections were 
carried out based on equivalent reflections using SADABS [66]. The structure was solved using 
Superflip [67,68] and refined against F2 in SHELXL [69,70] using Olex2 [71]. All of the non-
hydrogen atoms were refined anisotropically while all of the hydrogen atoms were located 
geometrically and refined using a riding model. Crystallographic data for the complex have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication CCDC 
1550949. Copies of the data can be obtained free of charge on application to CCDC, 12 Union 
Road, Cambridge CB2 1EZ, UK [fax(+44) 1223 336033, e-mail: deposit@ccdc.cam.ac.uk]. 
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